These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 29294158

  • 1. 18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
    Selnæs KM, Krüger-Stokke B, Elschot M, Willoch F, Størkersen Ø, Sandsmark E, Moestue SA, Tessem MB, Halvorsen D, Kjøbli E, Angelsen A, Langørgen S, Bertilsson H, Bathen TF.
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Aug; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
    Suzuki H, Jinnouchi S, Kaji Y, Kishida T, Kinoshita H, Yamaguchi S, Tobe T, Okamura T, Kawakita M, Furukawa J, Otaka A, Kakehi Y.
    Jpn J Clin Oncol; 2019 Sep 01; 49(9):803-811. PubMed ID: 31095314
    [Abstract] [Full Text] [Related]

  • 4. [18F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer.
    Alemozaffar M, Akintayo AA, Abiodun-Ojo OA, Patil D, Saeed F, Huang Y, Osunkoya AO, Goodman MM, Sanda M, Schuster DM.
    J Urol; 2020 Oct 01; 204(4):734-740. PubMed ID: 32347780
    [Abstract] [Full Text] [Related]

  • 5. Utility of 18F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study.
    Galgano SJ, McDonald AM, Rais-Bahrami S, Porter KK, Choudhary G, Burgan C, Bhambhvani P, Nix JW, Morgan DE, Li Y, Thomas JV, McConathy J.
    AJR Am J Roentgenol; 2021 Sep 01; 217(3):720-729. PubMed ID: 33052718
    [Abstract] [Full Text] [Related]

  • 6. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.
    BJU Int; 2012 Dec 01; 110(11):1666-71. PubMed ID: 22520686
    [Abstract] [Full Text] [Related]

  • 7. The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis.
    Kim SJ, Lee SW.
    Clin Radiol; 2019 Nov 01; 74(11):886-892. PubMed ID: 31358294
    [Abstract] [Full Text] [Related]

  • 8. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM.
    Eur J Nucl Med Mol Imaging; 2016 Sep 01; 43(10):1773-83. PubMed ID: 27091135
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
    Hoekstra RJ, Beulens A, Vrijhof EHJEJ, Wyndaele DNJ, Roef M, Brouwer LJM, Somford DM, Sedelaar M, van Basten JA.
    Nucl Med Commun; 2021 May 01; 42(5):476-481. PubMed ID: 33323869
    [Abstract] [Full Text] [Related]

  • 12. The Effect of Including Bone in Dixon-Based Attenuation Correction for 18F-Fluciclovine PET/MRI of Prostate Cancer.
    Elschot M, Selnæs KM, Johansen H, Krüger-Stokke B, Bertilsson H, Bathen TF.
    J Nucl Med; 2018 Dec 01; 59(12):1913-1917. PubMed ID: 29728516
    [Abstract] [Full Text] [Related]

  • 13. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
    Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
    Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284
    [Abstract] [Full Text] [Related]

  • 14. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.
    Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F.
    J Urol; 2017 Mar 15; 197(3 Pt 1):676-683. PubMed ID: 27746282
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y.
    Clin Nucl Med; 2020 May 15; 45(5):349-355. PubMed ID: 31977495
    [Abstract] [Full Text] [Related]

  • 16. Laparoscopic extended pelvic lymph node (LN) dissection as validation of the performance of [(11) C]-acetate positron emission tomography/computer tomography in the detection of LN metastasis in intermediate- and high-risk prostate cancer.
    Daouacher G, von Below C, Gestblom C, Ahlström H, Grzegorek R, Wassberg C, Sörensen J, Waldén M.
    BJU Int; 2016 Jul 15; 118(1):77-83. PubMed ID: 26074275
    [Abstract] [Full Text] [Related]

  • 17. A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.
    Elschot M, Selnæs KM, Sandsmark E, Krüger-Stokke B, Størkersen Ø, Tessem MB, Moestue SA, Bertilsson H, Bathen TF.
    Eur J Nucl Med Mol Imaging; 2017 Apr 15; 44(4):695-703. PubMed ID: 27817158
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, Malizia C, Ferrari M, Rigatti P, Fonti C, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2016 Aug 15; 43(9):1601-10. PubMed ID: 26960562
    [Abstract] [Full Text] [Related]

  • 20. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB.
    Int J Radiat Oncol Biol Phys; 2016 Sep 01; 96(1):206-13. PubMed ID: 27511856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.